Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Condition: Prostatitis
MeSH terms: Prostatitis; Pelvic Pain
Intervention: Alfuzosin; Placebo
Intervention MeSH terms: Alfuzosin
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 272.0
Sex: Male
Minimum age: 18 Years
Healthy volunteers: No
Keywords: Prostatitis; Non-bacterial Prostatitis; Prostatodynia; Alfuzosin; Alpha-adrenergic blocker

Summary:

      The purpose of this randomized clinical trial is to evaluate the efficacy and safety of the
      alpha adrenergic blocker Alfuzosin (Uroxatral) in men with relatively new onset of chronic
      prostatitis/chronic pelvic pain syndrome (CP/CPPS). Alfuzosin is a once daily (10 mg
      capsule), FDA approved medication for an indication in benign prostatic hyperplasia (BPH).
      The effectiveness of alfuzosin in improving lower urinary tract symptoms in patients with BPH
      has been documented in a number of placebo-controlled studies. A number of small studies have
      also suggested that alfuzosin ameliorates CP/CPPS symptoms through a similar alpha-blockade
      mechanism. This study will enable further testing of this hypothesis
    

Eligibility criteria:

        Inclusion Criteria:

          -  Participant has signed and dated the appropriate Informed Consent document.

          -  Participant is male.

          -  Participant is at least 18 years of age.

          -  Participant has had symptoms of discomfort or pain in the pelvic region for at least a
             six-week interval at the time of presentation.

          -  Symptoms bothersome enough to prompt a physician visit have been present for two years
             or less.

        Exclusion Criteria:

          -  Participant has evidence of facultative Gram negative or enterococcus with a value of
             greater than or equal to 1000 colony forming units (CFU) /ml in mid-stream urine
             (VB2).

          -  Participant has previously received alfuzosin (Uroxatral®), tamsulosin hydrochloride
             (Flomax®), doxazosin mesylate (Cardura®), terazosin hydrochloride (HCL) (Hytrin®), or
             other alpha-adrenergic receptor blockers for symptoms of CP/CPPS or within the past
             two years for any other reason.

          -  Participant has a history of prostate, penile, testicular, bladder, or urethral cancer
             or has undergone pelvic radiation, systemic chemotherapy, or intravesical
             chemotherapy.

          -  Participant has a history of moderate or severe hepatic impairment, severe renal
             sufficiency, severe or unstable cardiovascular (i.e. prolonged QT), respiratory,
             hematological, endocrinological, neurological or other somatic disorders.

          -  Participant has unilateral orchialgia without pelvic symptoms, active urethral
             stricture, or neurological disease or disorder affecting the bladder.

          -  Participant has uninvestigated, significant hematuria.

          -  Participant has undergone transurethral prostatectomy (TURP), transurethral incision
             of the prostate (TUIP), transurethral Incision or Resection of the Bladder Neck
             (TUIBN), transurethral microwave thermotherapy (TUMT), transurethral needle ablation
             (TUNA), balloon dilation of the prostate, open prostatectomy or any other prostate
             surgery or treatment such as cryotherapy or thermal therapy.

          -  Participant has a neurological impairment or psychiatric disorder preventing his
             understanding of consent and his ability to comply with the protocol.

          -  Participant is currently taking exclusionary medications such as potent CYP3A4
             inhibitors (i.e. ketoconazole, itraconazole, or ritonavir) or erythromycin.